B J Ansell

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program
    B J Ansell
    Division of General Internal Medicine Health Services Research, University of California, Los Angeles, School of Medicine, 90095, USA
    JAMA 282:2051-7. 1999
  2. ncbi request reprint Not getting to goal: the clinical costs of noncompliance
    Benjamin J Ansell
    The David Geffen School of Medicine at UCLA, UCLA School of Medicine, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
    J Manag Care Pharm 14:9-15. 2008
  3. doi request reprint Hyperlipidaemia and cardiovascular disease
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Opin Lipidol 19:433-4. 2008
  4. ncbi request reprint Targeting the anti-inflammatory effects of high-density lipoprotein
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA
    Am J Cardiol 100:n3-9. 2007
  5. ncbi request reprint The paradox of dysfunctional high-density lipoprotein
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Curr Opin Lipidol 18:427-34. 2007
  6. ncbi request reprint Modifying the anti-inflammatory effects of high-density lipoprotein
    Benjamin J Ansell
    Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 9:57-63. 2007
  7. ncbi request reprint High-density lipoprotein: is it always atheroprotective?
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 8:405-11. 2006
  8. ncbi request reprint A review of trials evaluating nonstatin lipid-lowering therapies
    Benjamin J Ansell
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 11:64-6. 2009
  9. ncbi request reprint Evidence for a combined approach to the management of hypertension and dyslipidemia
    Benjamin J Ansell
    Cholesterol Hypertension and Atherosclerosis Management Program, University of California Los Angeles, 200 UCLA Medical Plaza, Los Angeles, CA 90095, USA
    Am J Hypertens 18:1249-57. 2005
  10. ncbi request reprint Rationale for combination therapy with statin drugs in the treatment of dyslipidemia
    Benjamin J Ansell
    Division of General Internal Medicine Cardiology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 7:29-33. 2005

Detail Information

Publications29

  1. ncbi request reprint An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program
    B J Ansell
    Division of General Internal Medicine Health Services Research, University of California, Los Angeles, School of Medicine, 90095, USA
    JAMA 282:2051-7. 1999
    ....
  2. ncbi request reprint Not getting to goal: the clinical costs of noncompliance
    Benjamin J Ansell
    The David Geffen School of Medicine at UCLA, UCLA School of Medicine, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
    J Manag Care Pharm 14:9-15. 2008
    ..Despite overwhelming evidence in favor of statin use for lowering low-density lipoprotein cholesterol (LDL-C), medication compliance to these agents remains suboptimal, as it does in other disease states...
  3. doi request reprint Hyperlipidaemia and cardiovascular disease
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Opin Lipidol 19:433-4. 2008
  4. ncbi request reprint Targeting the anti-inflammatory effects of high-density lipoprotein
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA
    Am J Cardiol 100:n3-9. 2007
    ..In the future, characterizing and targeting functional aspects of HDLs may prove to offer therapeutic advantages over current treatment strategies...
  5. ncbi request reprint The paradox of dysfunctional high-density lipoprotein
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Curr Opin Lipidol 18:427-34. 2007
    ..This review addresses how, in atherosclerosis or systemic inflammation, HDL can lose its usual atheroprotective characteristics and even paradoxically assume proinflammatory properties...
  6. ncbi request reprint Modifying the anti-inflammatory effects of high-density lipoprotein
    Benjamin J Ansell
    Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 9:57-63. 2007
    ..Treatment with statins and/or apolipoprotein A1 mimetic peptides improves HDL's anti-inflammatory functions, and these as well as other medications may represent a novel pathway through which to target atherosclerosis...
  7. ncbi request reprint High-density lipoprotein: is it always atheroprotective?
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 8:405-11. 2006
    ..The presence of proinflammatory HDL coincides with conditions associated with chronic systemic inflammation, including atherosclerosis...
  8. ncbi request reprint A review of trials evaluating nonstatin lipid-lowering therapies
    Benjamin J Ansell
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 11:64-6. 2009
    ..Clinical trials currently in progress will more clearly delineate the cardiovascular effects of adding either ezetimibe or extended-release niacin/laropiprant to statin therapy...
  9. ncbi request reprint Evidence for a combined approach to the management of hypertension and dyslipidemia
    Benjamin J Ansell
    Cholesterol Hypertension and Atherosclerosis Management Program, University of California Los Angeles, 200 UCLA Medical Plaza, Los Angeles, CA 90095, USA
    Am J Hypertens 18:1249-57. 2005
    ..Furthermore, recent clinical trials, including those assessing atherosclerotic progression and CVD endpoints, have demonstrated the effectiveness of interventions targeted at multiple risk factors for CVD...
  10. ncbi request reprint Rationale for combination therapy with statin drugs in the treatment of dyslipidemia
    Benjamin J Ansell
    Division of General Internal Medicine Cardiology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 7:29-33. 2005
    ..More recently, however, it has been recognized that the potential complications of this combination are far outweighed by the clinical benefits that are possible...
  11. ncbi request reprint Developing a clinical strategy for cholesterol management in an era of unanswered questions
    B J Ansell
    Center for Primary Care Based Cardiovascular Disease Prevention, Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles School of Medicine, USA
    Am J Cardiol 88:25F-30F. 2001
    ..In the interim, a clinical strategy incorporating the lessons of recent clinical evidence is suggested...
  12. ncbi request reprint Anti-inflammatory properties of HDL
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Rev Endocr Metab Disord 5:351-8. 2004
  13. ncbi request reprint Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment
    Benjamin J Ansell
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095 1679, USA
    Circulation 108:2751-6. 2003
    ..The inflammatory/antiinflammatory properties of HDL were compared with HDL cholesterol in 2 groups of patients and in age- and sex-matched control subjects...
  14. ncbi request reprint Mechanisms of disease: proatherogenic HDL--an evolving field
    Mohamad Navab
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1679, USA
    Nat Clin Pract Endocrinol Metab 2:504-11. 2006
    ..The quality and function of HDL are also attractive targets for emerging therapies...
  15. ncbi request reprint Apolipoprotein A-I mimetic peptides
    Mohamad Navab
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095 1679, USA
    Arterioscler Thromb Vasc Biol 25:1325-31. 2005
    ..However, understanding these physical-chemical properties provides an explanation for the mechanism of action of the active peptides...
  16. ncbi request reprint The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL
    Mohamad Navab
    Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Lipid Res 45:993-1007. 2004
    ..Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides may both promote a reduction in oxidized lipids and enhance reverse cholesterol transport and therefore may have therapeutic potential...
  17. pmc Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis
    Bevra H Hahn
    Division of Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Arthritis Res Ther 10:213. 2008
    ....
  18. ncbi request reprint The double jeopardy of HDL
    Mohamad Navab
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1679, USA
    Ann Med 37:173-8. 2005
    ..Thus, HDL structure and function may be more important than HDL-cholesterol levels in predicting risk for cardiovascular disease...
  19. ncbi request reprint Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study
    Christina Charles-Schoeman
    Division of Rheumatology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, California 90095 1670, USA
    J Rheumatol 34:1459-64. 2007
    ..We examined the effects of atorvastatin 80 mg daily on the inflammatory properties of HDL and clinical disease activity in RA...
  20. ncbi request reprint The two faces of the 'good' cholesterol
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Cleve Clin J Med 74:697-700, 703-5. 2007
    ..Thus, the functional properties of HDL--not simply the level--may need to be considered and optimized...
  21. ncbi request reprint High-density lipoprotein function recent advances
    Benjamin J Ansell
    Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Am Coll Cardiol 46:1792-8. 2005
    ..Functional characterization of HDL is a promising method for enhanced assessment of cardiovascular risk and effectiveness of risk reduction...
  22. ncbi request reprint hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation
    Benjamin J Ansell
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Heart Dis 5:2-7. 2003
    ..The correlation between the reductions in CRP and LDL cholesterol differs from the findings of other published studies, and should prompt further investigation of the mechanism by which statins reduce CRP...
  23. ncbi request reprint Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey
    Benjamin J Ansell
    University of California at Los Angeles, Los Angeles, CA, USA
    Am Heart J 152:976-81. 2006
    ..This survey assessed and compared National Cholesterol Education Program (NCEP) Third Adult Treatment Panel lipid treatment goal achievement for men versus women undergoing treatment of dyslipidemia...
  24. ncbi request reprint HDL function as a target of lipid-modifying therapy
    Karol E Watson
    Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Rev Cardiovasc Med 8:1-8. 2007
    ..However, an increase in HDL-C did not lead to a decrease in cardiovascular events in all trials...
  25. ncbi request reprint Managing borderline levels of risk for coronary heart disease: two illustrative case presentations
    B J Ansell
    Division of General Internal Medicine and Health Services Research, UCLA Center for Primary Care-Based Cardiovascular Disease Prevention, UCLA School of Medicine, Los Angeles, Calif, USA
    J Am Osteopath Assoc 101:S12-6. 2001
    ....
  26. ncbi request reprint Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later
    Benjamin J Ansell
    Am J Cardiol 90:524-5. 2002
  27. ncbi request reprint High-density lipoprotein as a therapeutic target: a systematic review
    Inder M Singh
    Department of Cardiovascular Medicine, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, USA
    JAMA 298:786-98. 2007
    ..High-density lipoprotein cholesterol (HDL-C) is a cardiovascular risk factor that is gaining substantial interest as a therapeutic target...
  28. ncbi request reprint Improvement in current approaches to lipid lowering
    Benjamin J Ansell
    Am Fam Physician 65:783, 786-7. 2002
  29. ncbi request reprint Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Michael H Davidson
    Radiant Development, Chicago, Illinois, USA
    Am J Cardiol 96:556-63. 2005
    ..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...